Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, SomaLogic Ink Deal to Place SOMAscan Proteomics Platform in Academic, CRO Centers

NEW YORK (GenomeWeb News) – Agilent and SomaLogic said today that they have entered an agreement to expand access to Somalogic's SOMAscan protein biomarker discovery platform by placing it in select academic and contract research centers.

Somalogic has been offering the aptamer-based platform, which uses custom Agilent microarrays, out of its laboratory on a fee-for-service basis.

"This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market," Jacob Thaysen, vice president and general manager of Agilent's Genomics Solutions Division, said in a statement.

The SOMAscan platform uses SomaLogic's Slow Off-rate Modified Aptamer, or Somamer, affinity reagents to simultaneously quantify 1,129 protein analytes. These Somamers – essentially short strands of DNA – bind to protein targets in a sample of interest. They can then be quantified via microarrays, with the quantity of a given Somamer corresponding to the quantity of its target protein.

According to SomaLogic, the platform can work with samples as small as 50 μL and with a throughput of roughly 1,000 samples a week.

Financial and other terms were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.